1. Market Research
  2. > China Pharmaceuticals and Healthcare Report Q1 2017

China Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 152 pages

Includes 3 FREE quarterly updates


>BMI View:
Multinational drugmakers will face significant challenges in maintaining double-digit revenue growth rates in China. Reforms to the healthcare sector will continue over the coming quarters as authorities seek to expand healthcare access while containing costs in a macro environment that has seen economic growth slow. Provincial nuances will become more pertinent as the economic trajectories of each diverge and bidding processes differ. Collectively, this demands new approaches by multinational drugmakers to the China pharmaceutical market, integrating the macro-economic risk factors with a province level approach.

Headline Expenditure Projections

- Pharmaceuticals: CNY688bn (USD109bn) in 2015 to CNY766bn (USD115bn) by 2016; +11.5% in local currency terms and +5.4% in USD terms.

- Healthcare: CNY3,953bn (USD629bn) in 2015 to CNY4,424bn (USD665bn) in 2015; +11.9% in local currency and +5.8% in USD terms. In Q117, China is amongst the most attractive countries according to our Pharmaceutical Risk/Reward Index. The country scores 62.6 out of 100 and is ranked sixth amongst 19 other Asia Pacific countries. Key to China's strong score is its high market expenditure, high sector value growth and policy continuity. The only limiting factors come from the country's business transparency and limited legal diligence.

Table Of Contents

China Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (China 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (China 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (China 2012-2020) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (China 2012-2020) 22
Patented Drug Market Forecast 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (China 2012-2020) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (China 2012-2020) 26
OTC Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (China 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (China 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (China 2014-2020) 31
Industry Risk/Reward Index 32
Asia Pacific Risk/Reward Index - Q1 2017 32
China Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Regulatory Regime 40
Table: Important China GMP Deadlines 40
Intellectual Property Issues 42
Table: PhRMA's Special 301 submission, China, 2014-16 43
Pricing Regime 46
Reimbursement Regime 48
China - 13th Five-Year Plan To Reinforce Existing Trends 52
Market Overview 56
Healthcare Sector 56
Table: Healthcare Resources (China 2010-2015) 59
Table: Healthcare Personnel (China 2010-2015) 59
Table: Healthcare Activity (China 2010-2015) 60
Research and Development 64
Table: Selected List Of MNC With RandD Bases In China 65
Table: Selected List Of Collaboration In RandD Operations In China 68
Clinical Trials 69
Epidemiology 70
Table: Estimated Number Of New Cases Of Cancer In China 73
Competitive Landscape 74
Research-Based Industry 74
Table: Companies Represented by RDPAC 74
Table: Multinational Market Activity 75
Generic Drugmakers 77
Pharmaceutical Distribution 77
Company Profile 79
AstraZeneca 79
Bayer 84
China Shijiazhuang Pharmaceutical Group 88
Eli Lilly 90
GlaxoSmithKline 94
North China Pharmaceutical Corporation 99
Novartis 102
Merck and Co 106
Merck KGaA 109
Pfizer 112
Roche 116
Sanofi 120
Shanghai Pharmaceutical 124
Sinopharm 127
13th Five Year Plan 130
13th Five-Year Plan: Key Points 130
Summary Of Contents 130
Chapter 1: Overview 131
Table: Targets 131
Chapter 2: Innovation To Drive Development 132
Chapter 3: Economic Institutions 133
Chapter 4: Modernisation Of The Agricultural Sector 134
Chapter 5: Industries 135
Chapter 6: Expand The Network Economy 136
Chapter 7: Build A Modern Infrastructure Network 136
Chapter 8: New-Type Urbanisation 137
Chapter 9: Coordination Of Regional Development 138
Chapter 10: Environmental Protection 139
Chapter 11: Continue Opening Up 139
Others: 139
Demographic Forecast 141
Table: Population Headline Indicators (China 1990-2025) 142
Table: Key Population Ratios (China 1990-2025) 142
Table: Urban/Rural Population and Life Expectancy (China 1990-2025) 143
Table: Population By Age Group (China 1990-2025) 143
Table: Population By Age Group % (China 1990-2025) 144
Glossary 146
Methodology 148
Pharmaceutical Expenditure Forecast Model 148
Healthcare Expenditure Forecast Model 148
Notes On Methodology 149
Risk/Reward Index Methodology 150
Index Overview 151
Table: Pharmaceutical Risk/Reward Index Indicators 151
Indicator Weightings 152

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.